Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06891898 · ClinicalTrials.gov registry record
The iLet Experience Study
A clinical trial of Type 1 Diabetes, sponsored by Beta Bionics.
- Recruiting
- Registry status
- 1,875
- Enrollment target
- 1
- Study location
NCT06891898 is a study of Type 1 Diabetes that is actively recruiting participants, run by Beta Bionics. The registered enrollment target is 1,875 participants, above the 814-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (130% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06891898, a study of Type 1 Diabetes, is actively recruiting participants, sponsored by Beta Bionics.
- RECRUITING
- Registry status
- 1,875 participants
- Enrollment target
- 1
- Study location
Study Summary
A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decision Software during real-world use in people 6 years of age or older with type 1 diabetes (T1D) with 12 months follow-up.
Conditions Studied
Interventions
- DEVICE iLet Dosing Decision Software
Study Locations (1)
California
- Beta Bionics - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,875 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2027-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06891898
The ClinicalTrials.gov registry entry for NCT06891898 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,875 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 814-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (130% higher). The listed sponsor is Beta Bionics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which iLet Dosing Decision Software is the first listed.
NCT06891898 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06891898 about?
NCT06891898 is a clinical study titled "The iLet Experience Study". A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decision Software during real-world use in people 6 years of age or older with type 1 diabetes (T1D) with 12 months follow-up.
What is the current status of trial NCT06891898?
This trial is currently recruiting. The enrollment target is 1,875 participants. The study started on 2024-05-01. Estimated completion is 2027-06.
What conditions does trial NCT06891898 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT06891898?
The interventions under investigation include: iLet Dosing Decision Software (DEVICE).
Who is sponsoring clinical trial NCT06891898?
This trial is sponsored by Beta Bionics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06891898 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Multivariable Artificial Pancreas: Detecting and Mitigating Unannounced Physical Activity and Acute Psychological Stress
RECRUITING
-
Extended Bolus for Meals in a Closed-loop System
RECRUITING · Phase 4
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
AIDANET Pediatrics
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.